Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 25 | 2026 | 409 | 6.450 |
Why?
|
| Tuberculosis | 26 | 2026 | 538 | 5.940 |
Why?
|
| Tuberculosis, Pulmonary | 12 | 2026 | 230 | 3.500 |
Why?
|
| DNA Methylation | 5 | 2025 | 1032 | 1.820 |
Why?
|
| Feces | 5 | 2025 | 702 | 1.320 |
Why?
|
| Adaptive Immunity | 3 | 2021 | 99 | 1.250 |
Why?
|
| Sputum | 9 | 2025 | 117 | 1.210 |
Why?
|
| Molecular Diagnostic Techniques | 4 | 2023 | 167 | 1.120 |
Why?
|
| BCG Vaccine | 5 | 2023 | 105 | 1.110 |
Why?
|
| Immune Tolerance | 3 | 2024 | 154 | 1.100 |
Why?
|
| HIV Infections | 13 | 2025 | 1954 | 1.000 |
Why?
|
| Antitubercular Agents | 9 | 2025 | 263 | 0.990 |
Why?
|
| Interferon-gamma Release Tests | 4 | 2025 | 89 | 0.990 |
Why?
|
| Real-Time Polymerase Chain Reaction | 4 | 2025 | 524 | 0.890 |
Why?
|
| Citric Acid Cycle | 1 | 2024 | 42 | 0.870 |
Why?
|
| Lipopolysaccharides | 2 | 2025 | 291 | 0.840 |
Why?
|
| Epigenesis, Genetic | 4 | 2025 | 711 | 0.790 |
Why?
|
| Mycobacterium bovis | 1 | 2022 | 32 | 0.770 |
Why?
|
| Fetal Blood | 1 | 2023 | 174 | 0.760 |
Why?
|
| Sensitivity and Specificity | 14 | 2025 | 2080 | 0.720 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2021 | 115 | 0.620 |
Why?
|
| Bacteriological Techniques | 2 | 2016 | 85 | 0.600 |
Why?
|
| Leukocytes | 1 | 2020 | 204 | 0.590 |
Why?
|
| Ascaris lumbricoides | 1 | 2018 | 19 | 0.570 |
Why?
|
| Schistosoma haematobium | 1 | 2018 | 17 | 0.570 |
Why?
|
| Schistosomiasis | 1 | 2018 | 52 | 0.550 |
Why?
|
| Transcriptome | 3 | 2026 | 1069 | 0.540 |
Why?
|
| Immunity, Innate | 2 | 2021 | 395 | 0.540 |
Why?
|
| Ascariasis | 1 | 2018 | 73 | 0.530 |
Why?
|
| Th1 Cells | 1 | 2018 | 154 | 0.530 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2017 | 479 | 0.520 |
Why?
|
| Schistosoma | 1 | 2016 | 13 | 0.490 |
Why?
|
| Immunologic Factors | 2 | 2021 | 182 | 0.480 |
Why?
|
| Humans | 53 | 2026 | 127455 | 0.470 |
Why?
|
| Antigens, Helminth | 1 | 2016 | 187 | 0.450 |
Why?
|
| Population Surveillance | 2 | 2022 | 395 | 0.440 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 2 | 2025 | 81 | 0.390 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2314 | 0.360 |
Why?
|
| Macrophages | 1 | 2016 | 643 | 0.360 |
Why?
|
| Immunologic Memory | 2 | 2021 | 194 | 0.310 |
Why?
|
| Antigens, Bacterial | 2 | 2025 | 313 | 0.300 |
Why?
|
| Child | 16 | 2025 | 25296 | 0.290 |
Why?
|
| Signal Transduction | 1 | 2020 | 4489 | 0.280 |
Why?
|
| Cytokines | 4 | 2026 | 1326 | 0.270 |
Why?
|
| Interferon-gamma | 3 | 2025 | 528 | 0.270 |
Why?
|
| Interleukin-4 | 2 | 2018 | 144 | 0.260 |
Why?
|
| T-Lymphocytes | 2 | 2025 | 1711 | 0.250 |
Why?
|
| South Africa | 2 | 2023 | 99 | 0.240 |
Why?
|
| Inflammation | 2 | 2022 | 1434 | 0.220 |
Why?
|
| Succinates | 1 | 2024 | 19 | 0.220 |
Why?
|
| Succinic Acid | 1 | 2024 | 13 | 0.220 |
Why?
|
| Animals | 8 | 2024 | 33205 | 0.220 |
Why?
|
| Child, Preschool | 8 | 2025 | 14462 | 0.220 |
Why?
|
| DNA, Bacterial | 2 | 2024 | 482 | 0.220 |
Why?
|
| Everolimus | 1 | 2024 | 48 | 0.220 |
Why?
|
| Biomarkers | 2 | 2024 | 3252 | 0.210 |
Why?
|
| Gene Silencing | 1 | 2025 | 224 | 0.210 |
Why?
|
| Adolescent | 11 | 2025 | 20154 | 0.210 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2018 | 382 | 0.210 |
Why?
|
| Adult | 15 | 2025 | 30579 | 0.210 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2025 | 900 | 0.210 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2025 | 148 | 0.200 |
Why?
|
| Young Adult | 6 | 2025 | 9703 | 0.190 |
Why?
|
| Immunity | 1 | 2023 | 175 | 0.190 |
Why?
|
| Ultraviolet Therapy | 1 | 2022 | 2 | 0.190 |
Why?
|
| Prospective Studies | 8 | 2025 | 6249 | 0.190 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2022 | 22 | 0.190 |
Why?
|
| CRISPR-Cas Systems | 1 | 2025 | 277 | 0.190 |
Why?
|
| Immunocompromised Host | 2 | 2021 | 303 | 0.180 |
Why?
|
| Guinea Pigs | 1 | 2022 | 157 | 0.180 |
Why?
|
| Isosporiasis | 1 | 2021 | 3 | 0.180 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 50 | 0.180 |
Why?
|
| Sexual and Gender Minorities | 1 | 2022 | 67 | 0.180 |
Why?
|
| Cryptococcus | 1 | 2021 | 3 | 0.170 |
Why?
|
| Herpesvirus 8, Human | 1 | 2021 | 46 | 0.170 |
Why?
|
| Systems Biology | 1 | 2021 | 60 | 0.170 |
Why?
|
| Cryptococcosis | 1 | 2021 | 40 | 0.170 |
Why?
|
| Kava | 1 | 2020 | 8 | 0.170 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 69 | 0.170 |
Why?
|
| Allergy and Immunology | 1 | 2021 | 31 | 0.170 |
Why?
|
| Vaccination | 2 | 2023 | 1004 | 0.170 |
Why?
|
| History, 19th Century | 1 | 2021 | 110 | 0.170 |
Why?
|
| Coinfection | 2 | 2025 | 185 | 0.160 |
Why?
|
| Mozambique | 3 | 2025 | 19 | 0.160 |
Why?
|
| Eosinophilia | 1 | 2021 | 104 | 0.160 |
Why?
|
| Sarcoma, Kaposi | 1 | 2021 | 123 | 0.160 |
Why?
|
| Cellular Senescence | 1 | 2022 | 199 | 0.160 |
Why?
|
| Herpesviridae Infections | 1 | 2021 | 139 | 0.160 |
Why?
|
| Urologic Neoplasms | 1 | 2020 | 37 | 0.160 |
Why?
|
| Case-Control Studies | 2 | 2025 | 3331 | 0.160 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2021 | 225 | 0.160 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 73 | 0.160 |
Why?
|
| Diarrhea | 1 | 2021 | 305 | 0.160 |
Why?
|
| Anti-HIV Agents | 1 | 2023 | 346 | 0.150 |
Why?
|
| History, 20th Century | 1 | 2021 | 370 | 0.150 |
Why?
|
| RNA | 1 | 2022 | 518 | 0.150 |
Why?
|
| Gene Expression | 1 | 2023 | 1487 | 0.150 |
Why?
|
| Immunization | 1 | 2020 | 304 | 0.150 |
Why?
|
| Health Personnel | 1 | 2023 | 535 | 0.140 |
Why?
|
| Receptors, Cytokine | 1 | 2018 | 65 | 0.140 |
Why?
|
| Uganda | 3 | 2025 | 94 | 0.140 |
Why?
|
| Colony Count, Microbial | 1 | 2018 | 86 | 0.140 |
Why?
|
| Limit of Detection | 1 | 2018 | 74 | 0.140 |
Why?
|
| Autoantibodies | 1 | 2021 | 423 | 0.140 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2018 | 36 | 0.140 |
Why?
|
| Male | 15 | 2025 | 62861 | 0.140 |
Why?
|
| Mycobacterium chelonae | 1 | 2017 | 4 | 0.140 |
Why?
|
| Skin | 2 | 2017 | 517 | 0.130 |
Why?
|
| Precision Medicine | 1 | 2020 | 346 | 0.130 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2017 | 45 | 0.130 |
Why?
|
| Viral Vaccines | 1 | 2020 | 313 | 0.130 |
Why?
|
| Female | 14 | 2025 | 68733 | 0.130 |
Why?
|
| Age Factors | 1 | 2023 | 2814 | 0.130 |
Why?
|
| Tanzania | 3 | 2024 | 63 | 0.130 |
Why?
|
| Helminths | 1 | 2017 | 51 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 285 | 0.130 |
Why?
|
| Calibration | 1 | 2016 | 95 | 0.120 |
Why?
|
| Risk Factors | 3 | 2026 | 10631 | 0.120 |
Why?
|
| CD56 Antigen | 1 | 2016 | 26 | 0.120 |
Why?
|
| Phagosomes | 1 | 2016 | 37 | 0.120 |
Why?
|
| Hookworm Infections | 1 | 2017 | 125 | 0.120 |
Why?
|
| Dermoscopy | 1 | 2015 | 2 | 0.120 |
Why?
|
| CD3 Complex | 1 | 2016 | 91 | 0.120 |
Why?
|
| Reference Standards | 1 | 2016 | 230 | 0.120 |
Why?
|
| Intravital Microscopy | 1 | 2015 | 18 | 0.120 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 197 | 0.110 |
Why?
|
| Immunophenotyping | 1 | 2016 | 330 | 0.110 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 2893 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2021 | 4987 | 0.110 |
Why?
|
| Age of Onset | 1 | 2016 | 611 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 363 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 376 | 0.110 |
Why?
|
| Interleukin-10 | 1 | 2016 | 181 | 0.110 |
Why?
|
| Latent Tuberculosis | 1 | 2016 | 76 | 0.110 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 342 | 0.110 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 109 | 0.110 |
Why?
|
| Lysosomes | 1 | 2016 | 248 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 662 | 0.110 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 361 | 0.110 |
Why?
|
| Flow Cytometry | 1 | 2016 | 755 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 439 | 0.100 |
Why?
|
| Africa South of the Sahara | 2 | 2025 | 115 | 0.100 |
Why?
|
| Prognosis | 2 | 2026 | 4803 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1141 | 0.090 |
Why?
|
| Cells, Cultured | 1 | 2018 | 2899 | 0.090 |
Why?
|
| Pathology, Molecular | 2 | 2022 | 63 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2025 | 226 | 0.090 |
Why?
|
| Middle Aged | 7 | 2025 | 27867 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2400 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 2239 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 1759 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 4445 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2018 | 2345 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 880 | 0.070 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2007 | 18 | 0.070 |
Why?
|
| Infant | 5 | 2025 | 12806 | 0.070 |
Why?
|
| Mice | 1 | 2024 | 17693 | 0.070 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2007 | 52 | 0.070 |
Why?
|
| Time Factors | 1 | 2016 | 6169 | 0.060 |
Why?
|
| Aged | 2 | 2023 | 20494 | 0.060 |
Why?
|
| Geriatric Psychiatry | 1 | 2006 | 12 | 0.060 |
Why?
|
| Foreign Medical Graduates | 1 | 2006 | 11 | 0.060 |
Why?
|
| Alaska | 1 | 2025 | 8 | 0.060 |
Why?
|
| Phenotype | 2 | 2026 | 4309 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 2519 | 0.060 |
Why?
|
| Family Practice | 1 | 2006 | 86 | 0.060 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2025 | 19 | 0.060 |
Why?
|
| Macrophages, Alveolar | 1 | 2025 | 48 | 0.060 |
Why?
|
| Jurkat Cells | 1 | 2025 | 84 | 0.060 |
Why?
|
| Tuberculin Test | 1 | 2025 | 120 | 0.050 |
Why?
|
| HIV-1 | 1 | 2007 | 469 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2025 | 320 | 0.050 |
Why?
|
| Host-Pathogen Interactions | 1 | 2026 | 251 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 291 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 1867 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2025 | 672 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2025 | 823 | 0.050 |
Why?
|
| Gene Editing | 1 | 2025 | 197 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2022 | 63 | 0.050 |
Why?
|
| HEK293 Cells | 1 | 2025 | 770 | 0.050 |
Why?
|
| Kenya | 1 | 2022 | 58 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2006 | 462 | 0.050 |
Why?
|
| Phototherapy | 1 | 2022 | 36 | 0.050 |
Why?
|
| Isospora | 1 | 2021 | 3 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2017 | 261 | 0.040 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2021 | 44 | 0.040 |
Why?
|
| HIV | 1 | 2023 | 171 | 0.040 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2022 | 72 | 0.040 |
Why?
|
| Anti-Retroviral Agents | 1 | 2023 | 145 | 0.040 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2021 | 19 | 0.040 |
Why?
|
| Invasive Fungal Infections | 1 | 2021 | 19 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2022 | 12580 | 0.040 |
Why?
|
| Isoniazid | 1 | 2021 | 64 | 0.040 |
Why?
|
| Minority Groups | 1 | 2022 | 256 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2021 | 188 | 0.040 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2021 | 131 | 0.040 |
Why?
|
| Cell Line | 1 | 2025 | 2565 | 0.040 |
Why?
|
| Rituximab | 1 | 2021 | 166 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2021 | 287 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 1110 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2006 | 779 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 362 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 1371 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 200 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 264 | 0.040 |
Why?
|
| United States | 3 | 2022 | 11399 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2021 | 299 | 0.040 |
Why?
|
| Family Characteristics | 1 | 2019 | 97 | 0.040 |
Why?
|
| Syndrome | 1 | 2021 | 1137 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 1148 | 0.030 |
Why?
|
| Metabolomics | 1 | 2021 | 455 | 0.030 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2017 | 52 | 0.030 |
Why?
|
| DNA | 1 | 2022 | 1422 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2017 | 124 | 0.030 |
Why?
|
| Photometry | 1 | 2015 | 4 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2021 | 776 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2006 | 1198 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 686 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2026 | 3269 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2017 | 299 | 0.030 |
Why?
|
| Rural Population | 1 | 2017 | 247 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 1237 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1871 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 1548 | 0.020 |
Why?
|
| Lung | 1 | 2021 | 1522 | 0.020 |
Why?
|
| Mutation | 1 | 2025 | 5948 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2023 | 17076 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2006 | 175 | 0.010 |
Why?
|
| Data Collection | 1 | 2006 | 370 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2017 | 8368 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2006 | 1021 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 3937 | 0.010 |
Why?
|